ABOUT LYMPHOMA

A simpler 2-drug regimen of bendamustine plus rituximab has the potential to become the new standard first-line therapy for indolent NHL, in place of the current standard regimen of rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), and prednisone (R-CHOP). Adverse events for the two drug regimens are shown. The 2-drug combination significantly improved progression-free survival to 54.8 months, compared to 34.8 months with R-CHOP—a gain of 20 months.^[13]


FROM MEDSCAPE
----------------------------